Market Overview

UPDATE: Jefferies Downgrades HealthSouth Corporation to Hold on Regulatory Headwinds

Share:
Related HLS
5 NYSE Healthcare Stocks With The Highest ROE
Benzinga's M&A Chatter for Thursday June 11, 2015

Jefferies lowered its HealthSouth Corporation (NYSE: HLS) rating from Buy to Hold and reduced its price target from $25 to $23.

Jefferies noted, "HLS's strong Q2 performance and raised guidance was impressive, but we recommend taking advantage of stock strength to lighten long positions, fearing that IRF reimbursement could get greater scrutiny later this year when legislators look for funding offsets to another doc fix and deficit reduction."

HealthSouth Corporation closed at $22.93 on Thursday.

Latest Ratings for HLS

DateFirmActionFromTo
Jun 2015Deutsche BankMaintainsHold
Jun 2015WedbushInitiates Coverage onNeutral
Jun 2015UBSMaintainsNeutral

View More Analyst Ratings for HLS
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (HLS)

Around the Web, We're Loving...

Get Benzinga's Newsletters